John Chisholm
Analyst · Stephens Inc. Please go ahead with you question
Chris, thank you. I would also like to welcome each of you to Flotek’s third quarter 2015 conference call. We are glad you are here. With me today are Rob Schmitz, Flotek’s Chief Financial Officer; Steve Reeves, our Executive Vice President of Operations; Josh Snively, President of our Florida Chemical subsidiary as well as our Executive Vice President of Research and Innovation; Rich Walton, Flotek’s Chief Financial Officer, Emeritus; Chris Edmonds, who you just heard from, our Senior Director of Corporate Finance and Strategy. Also I’m honored to welcome John Ely sitting to my left, Principal of Ely & Associates, a leading international completion analytics and consulting firm based here in Huston. In addition to being a Founder of one of the most recognized completion consultancies in the world, John has spent his entire 50 year career focused on optimizing completion design as they celebrated oilfield chemist analyzing and gas tinkering [ph] with completion chemistries around the globe. John is here to discuss the recently announced partnership between Flotek and his firm, his views on advanced completion chemistries, as well as answer your questions regarding our partnership, as well as on completion design and the uses of various chemistries and optimizing completions with the result in maximizing production. John, we are glad you are here. Last evening we filed our quarterly report with the U.S. Securities and Exchange Commission, but we won’t take your valuable time to regurgitate those filings. We will provide a summary of the results, attempt to add some color regarding current operations, as well as a sense of our future and be happy to answer your questions. However, before doing so a couple of opening comments. As noted last night Flotek reported revenue for the quarter ended September 30, 2015 of $87.9 million, a 1% increase compared with second quarter 2015. In our view the worst oil field operating environment in my 30 plus years in the business and one that became consistently less attractive throughout the third quarter, Flotek’s ability to post both revenue and profit growth is a testament to the commitment of the woman and men of Flotek, as well as the continued acceleration of acceptance of Flotek’s key completion chemistries, a fact we will discuss in more detail shortly. Not only did Flotek post sales growth in the quarter, such growth resulted in improved profit as well. Flotek posted profits of $2 million or $0.04 per fully diluted common share that compares to fully diluted earnings of $0.02 per share last quarter excluding non-recurring items. Over the course of my six years at Flotek we worked diligently to position our company as a technology leader in the oil field, especially in the area of completion chemistry. Our third quarter we believe shows that effort has been effective as we expect to be one of the only oil field concerns that will show both top and bottom line growth. Moreover, our energy chemistry segment not only continues to achieve strong market penetration due to our hallmark CnF completion chemistry. The segment also showed meaningful growth in both gross margins and operating margins. Again, primarily due to growth in CnF revenues and pricing stability in CnF. Specifically as noted in the press release last evening, like product pricing among CnF remain nearly constant in the third quarter, contrary to some erroneous reports. To be able to say third quarter energy chemistry gross profits were 18.8% above second quarter levels and operating income was over 20.1% higher than the previous quarter, in this operating environment is in my view a near heroic achievement and breathtaking. Moreover, that didn’t happen by chance, but rather by the incredible effort of the nearly 500 people at Flotek who care about making the difference to our shareholders, and it happens because we have worked tirelessly to ensure we have a chemistry technology that has empirically shown to improve completion outcomes and as a result making a difference in the economic performance for our clients. That is the reason that with activity down over 50% in the course of the year, CnF sales volumes in the third quarter of 2015 were 59% above third quarter 2014 sales and increased 34% sequentially. That said, we understand that isn’t good enough. As such while pleased with our progress, especially in energy chemistry, we are not yet satisfied. Our progress and success in the quarter simply makes us more enthused about future opportunities and we will continue to work smarter and harder to ensure we remain focused and continually gain market share with our technologies and as importantly are appropriately positioned to turn current market challenges into opportunities for Flotek and its stakeholders. While that may not happen overnight or even in the fourth quarter, we are convinced we are positioned as a company and with partners like John Ely, so that 2016 will be better than 2015 and we will create new opportunities to create value for you, our shareholders. No doubt we are realistic about the industry headwinds and challenges we face in the short term. With the challenges already faced in 2015, combined with the holidays quickly approaching, we understand there is a real possibility that oil field activity in the last several weeks of the year could slow precipitously. However, we have a strong backlog of validations in the pipeline, including projects with major independence that we believe will continue to move forward, albeit perhaps more deliberately as we approach year end and we expect those projects to re-energize into the New Year. And who knows, several of our analysts were skeptical that third quarter chemistry sales could be better than second quarter results, but they were. Our goal is to improve each and every day regardless of the hand we are dealt. While realistic, we will look for every opportunity to operationalize that mantra even in the fourth quarter. As we have said many times, the adoption or transformation of game changing technology is not a linear process. But as our results over the past two quarters strongly suggest, the rate of adoption of our production maximizing precision customized chemistries can grow in the environment presented over the past six months, we are certain the long term future of Flotek is as wide as ever and expect significant opportunities for growth in the coming year. Before I turn the call over to Rob Schmitz to provide additional financial review, I want to take a minute to discuss an issue of interest to all Flotek investors of which all of us around this table today are. We appreciate the thoughts and work and effort that many of the analysts who cover Flotek provide and we understand how difficult the economic analysis of a company like Flotek can be, especially in an environment with such high levels of uncertainty. That said, the challenges and the analysis business also create challenges for companies like Flotek, especially when one erroneous estimate can have such a disproportionate impact on consensus numbers, which is what happened in the third quarter. Removing just that one estimate in the mix provides a more cogent view of consensus taken and makes Flotek’s third quarter results not only at or near the top of the service sector, but slightly ahead of the mainstream consensus. Please understand, we appreciate the effort of those in the complete and accurate coverage of our company and have no interest in the debate over valuation and reading calls that are based on factual and accurate information. That is what makes the U.S. public market so robust. However, accurate based mathematics, factual statements that don’t involve blind conjectural or guess as to material facts such as customers or key chemistry performance and correct statements of fact about items such as the current status of credit agreements and the like that can easily be located in our public filings seem like basic tenants of objective thorough securities research. While we have little control over what is published in today’s world, I would say we welcome firms and analysts that have an interest in factual, constructive evaluation and will feel compelled going forward to mention those who appear to potentially have agendas other than objective securities analysis and critic. That said, the Flotek team is acutely focused on what we can control, especially in challenging times like today. By creating best-in-class for the field chemistry, providing support to our clients to ensure optimal completion design and execution, creating objective evaluation tools that show performance of our chemistry, working to improve our processes to ensure maximum operational efficiency, looking for opportunities to expand our reach and grow our business both intrinsically and extrinsically by maintaining a superior affinity profile and operating a business guided, our core principles for safety, fairness and a sense of ecos [ph] unrivaled by our peers. We will be vigilant in our scrutiny of cyclical variables outside our direct control using them as guides to help optimize our operations through the cycle. As I said on each call since I took the hand over six years ago, it continues to be my privilege to serve as President of the company. I remain immensely proud and humble by the commitment and support of member of the Flotek team that believe as a group we can make a difference in the future of Flotek combined to our vision, that technology can make the difference for all of our stakeholders. Regardless of the challenges presented by the current operating environment, I remain enthused through the efforts of our people, the future that’s filled with opportunities to create value for our stakeholders. With that, I’d like to turn the call over to Rob Schmitz to review our third quarter financial highlights and provide some additional color on certain financial issues. Rob.